Advertisement
Advertisement
U.S. markets close in 6 hours
Advertisement
Advertisement
Advertisement
Advertisement

Core One Labs Inc. (COOL.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.40500.0000 (0.00%)
As of 03:53PM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.4050
Open0.0000
Bid0.3700 x N/A
Ask0.4150 x N/A
Day's Range0.4050 - 0.4050
52 Week Range0.3500 - 6.3800
Volume0
Avg. Volume38,003
Market Cap6.286M
Beta (5Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-5.0900
Earnings DateMay 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for COOL.CN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Core One Labs’ Upgrades to OTCQB Venture Market

      VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology is pleased to announce that it has

    • GlobeNewswire

      Core One Labs’ Akome Receives Positive Results from Bioassay Studies

      Will Look to Advance its Psychedelic Based FormulationsVANCOUVER, British Columbia, April 02, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) through a research arrangement with Neuro-Zone Srl, (“Neuro-Zone”) based in Bresso, Italy, has achieved positive results from its in vitro biological assay (“bioassay”) development studies (

    • GlobeNewswire

      Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities

      VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies. “Acquisition or investment by a major pharmaceutical company could be mutually beneficial. As more research comes to light regar

    Advertisement
    Advertisement